-transparent.png){kind=logo}
Synergistic cell killing of human lymphoblastic leukemia cell line, CCRF-CEM, occurred when hydroxyurea (HU) was administered before 1-beta-D-arabinofuranosylcytosine (ara-C). At the optimal dose of HU (1mM), the ara-CTP concentration increased 4-fold and the intracellular accumulation of ara-C increased 4-fold, while the dCTP concentration decreased by more than 50%. Increased intracellular accumulation of ara-C after HU treatment was also observed in human acute myelogenous leukemic cells in circulating blood. Therefore, the synergistic cell kill of HU and ara-C may be the consequence of greater inhibition of DNA polymerase by the increased level of ara-CTP in the presence of the decreased concentration of the natural substrate of this enzyme, dCTP. This synergism was not due to an increased incorporation of ara-C into DNA since the treatment of cells with HU did not enhance the ara-C incorporation into DNA but rather suppressed it.
M Tanaka, and
K Kimura, and
S Yoshida
May 1983,
British journal of cancer,
M Tanaka, and
K Kimura, and
S Yoshida
September 1979,
The Journal of clinical investigation,
M Tanaka, and
K Kimura, and
S Yoshida
May 1994,
Mutagenesis,
M Tanaka, and
K Kimura, and
S Yoshida
June 1983,
Journal of cellular physiology,
M Tanaka, and
K Kimura, and
S Yoshida
January 1986,
Folia haematologica (Leipzig, Germany : 1928),
M Tanaka, and
K Kimura, and
S Yoshida
December 1976,
The Journal of pharmacy and pharmacology,
M Tanaka, and
K Kimura, and
S Yoshida
January 1978,
Chemotherapy,
M Tanaka, and
K Kimura, and
S Yoshida
November 1974,
Nature,
M Tanaka, and
K Kimura, and
S Yoshida
January 1979,
Archivum immunologiae et therapiae experimentalis,
M Tanaka, and
K Kimura, and
S Yoshida
December 1990,
Acta medica Okayama,
